Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Profit After Tax (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Profit After Tax for 4 consecutive years, with -$27.9 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax fell 48.26% to -$27.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$109.0 million through Dec 2025, down 22.06% year-over-year, with the annual reading at -$109.0 million for FY2025, 22.06% down from the prior year.
  • Profit After Tax hit -$27.9 million in Q4 2025 for Taysha Gene Therapies, up from -$32.7 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $47.7 million in Q4 2023 to a low of -$117.1 million in Q3 2023.
  • Historically, Profit After Tax has averaged -$29.7 million across 4 years, with a median of -$26.0 million in 2022.
  • Biggest YoY gain for Profit After Tax was 186.68% in 2023; the steepest drop was 341.39% in 2023.
  • Year by year, Profit After Tax stood at -$55.1 million in 2022, then skyrocketed by 186.68% to $47.7 million in 2023, then plummeted by 139.35% to -$18.8 million in 2024, then tumbled by 48.26% to -$27.9 million in 2025.
  • Business Quant data shows Profit After Tax for TSHA at -$27.9 million in Q4 2025, -$32.7 million in Q3 2025, and -$26.9 million in Q2 2025.